Phase 1 Prostate Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older.
• People who have given written consent to take part (or whose legal representative has done so on their behalf).
• People who agree to allow stored tumour tissue samples from a previous biopsy to be used for research purposes.
• People who have a general health and activity level rated as reasonably functional, as measured by standard medical scoring tools (confirm with trial site).
• People who have prostate cancer that has spread and is no longer responding to hormone-lowering treatments, with testosterone levels kept very low either through surgery or ongoing medication.
• People whose tumour tissue tests positive for a protein called PSCA, as assessed by the trial laboratory.
• People whose cancer has continued to grow or spread despite having received at least one advanced hormone-blocking therapy (such as abiraterone or enzalutamide), shown either by rising PSA blood test results or new spots visible on scans.
• People who have fully recovered from side effects of previous cancer treatments (except hair loss), with only mild or no remaining effects.
• People who had chemotherapy at least 2 weeks before the blood collection procedure (leukapheresis).
• People who had prior radiotherapy, provided it was completed more than 14 days before leukapheresis and was not the only measurable site of disease.
• People who have no known medical reasons preventing them from undergoing leukapheresis (a procedure to collect white blood cells), or from receiving steroids or the medication tocilizumab.
• People whose recent blood test results show adequate white blood cell counts, platelet levels, liver function, and kidney function, within ranges specified by the trial (confirm with trial site for exact values).
• People whose heart tracing (ECG) shows no significant abnormalities requiring urgent attention.
• People who test negative for HIV, hepatitis B, hepatitis C, and syphilis (or, if certain results are borderline, whose virus levels are undetectable on further testing).
• Males who are able to father children and who agree to use effective contraception or abstain from heterosexual activity during the study and for at least 3 months after the last treatment.
• For one specific treatment plan in the trial: people who have between one and three tumour spots that have not previously been treated with radiation and that are considered safe to treat with a specific radiation dose (confirm with trial site).

Who may not be able to join:

• People who are currently using ongoing steroid tablets or other medicines that suppress the immune system (note: regular low-dose steroid replacement or inhaled steroids are generally not disqualifying — confirm with trial site).
• People who have significant heart rhythm problems that are not well controlled with medication within two weeks of screening.
• People who have a known history of optic neuritis (inflammation of the eye's nerve), seizures, or other inflammatory or immune conditions affecting the brain or nervous system.
• People who have had a serious allergic reaction to medicines with a similar makeup to the study treatment.
• People who have known bleeding disorders, such as haemophilia or von Willebrand's disease.
• People who have had a stroke or bleeding in the brain within the 6 months before screening.
• People who have had another type of cancer, unless it was treated with the intent to cure, has shown no signs of returning for 3 or more years, or was a limited skin cancer or early-stage bladder cancer (confirm with trial site for specific details).
• People who have a significant uncontrolled medical illness.
• People who have an active infection currently being treated with antibiotics.
• People who have a known history of HIV, hepatitis B, or hepatitis C infection.
• People for whom the trial investigator believes participation would not be safe for medical reasons.
• People who, in the investigator's opinion, may not be able to follow all the requirements of the study.

Important: Always verify eligibility with the trial site directly before applying.